Percheron Therapeutics (ASX:PER) said it entered into a worldwide exclusive license agreement with Hummingbird Bioscience to develop, manufacture, and commercialize HMBD-002, a monoclonal antibody therapy, for an upfront payment of $3 million, as well as contingent payments and royalties, according to a Thursday ASX filing.
Percheron will make contingent milestone payments to the Singapore-based firm of up to $287 million as well as pay royalties on net sales of a commercial product, with the first tier incurring a royalty of 12.5%.
It plans to conduct a clinical trial for HMBD-002 in 2026. Hummingbird will provide a batch of drug substance for use in future clinical trials.
A phase one clinical trial for HMBD-002 was completed in the US, under an investigational new drug application with the Food and Drug Administration, which showed the drug candidate to be pharmacologically active and generally safe and well-tolerated.
Percheron's shares jumped 5% in recent trading on Thursday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。